Ignite Creation Date:
2024-05-06 @ 7:52 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06161545
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2023-12-04
Brief Title:
Pembrolizumab N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-18
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-04
First Submit QC Date:
December 7 2023
Study First Post Date:
2023-12-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-23
Last Update Post Date:
2024-07-15
Last Update Post Date Type:
ESTIMATED